drugset / Trial / NCT06368921

A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors

NCT06368921

Phase 1 Recruiting 30 enrolled Guangzhou Virotech Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To Evaluate the safety and tolerability of single and multiple intratumoral injections of recombinant oncolytic virus M1 (VRT106) in patients with locally advanced/metastatic solid tumors.

Timeline

Start
2024-06-19
Primary completion
2026-09
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject VRT106 Unknown Other

Indications